Delving into the Latest Updates on Jingmaiyan Granules with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular DiseasesOther Diseases

Active Indication

Superficial Thrombophlebitis

Inactive Indication-

Originator Organization-

Active Organization

Jiangsu Kanion Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

1. To preliminarily evaluate the effectiveness and safety of phlebitis granules in the treatment of acute stage of superficial thrombophlebitis (blood heat and stasis syndrome); 2. To explore the relationship between clinical dose and clinical effect of phlebitis granules in the treatment of acute stage of superficial thrombophlebitis (blood heat and stasis syndrome), and provide a basis for the next clinical trial.

Start Date29 Mar 2023

Sponsor / Collaborator

Shanghai Tufeng Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with Jingmaiyan Granules

Login to view more data

100 Translational Medicine associated with Jingmaiyan Granules

Login to view more data

100 Patents (Medical) associated with Jingmaiyan Granules

Login to view more data

100 Deals associated with Jingmaiyan Granules

Login to view more data